Fatty liver diseases, including alcohol-associated liver disease (ALD) and nonalcoholic fatty
liver disease nonalcoholic fatty liver disease (NAFLD), affect a large number of people
worldwide and become one of the major causes of end-stage liver disease, such as liver
cirrhosis and hepatocellular carcinoma (HCC). Unfortunately, there are currently no
approved pharmacological treatments for ALD or NAFLD. This situation highlights the urgent
need to explore new intervention targets and discover effective therapeutics for ALD and …